Associations and indications of Ki67 expression with clinicopathological parameters and molecular subtypes in invasive breast cancer: A population-based study

Oncology Letters

Volumn 10, Issue 3, 2015, Pages 1741-1748

  Sun, Jinzhong ^a,b   Chen, Chuang ^a   Wei, Wen ^a   Zheng, Hongmei ^c   Yuan, Jingping ^d,e   Tu, Yi ^a   Yao, Feng ^a   Wang, Lijun ^a   Yao, Xiaoli ^a   Li, Juanjuan ^a   Li, Yan ^d   Sun, Shengrong ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c HUBEI CANCER HOSPITAL   (China)

^d ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^e CENTRAL HOSPITAL OF WUHAN   (China)

Author keywords

Breast cancer; Clinicopathological parameters; Ki67; Molecular subtypes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TUMOR VOLUME;

EID: 84937410836     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3461     Document Type: Article

References (27)

1. Jemal A, Bray F, CenterMM, FerlayJ, WardE and FormanD: Global cancer statistics. CACancerJClin61: 69-90, 2011.
2. Gerdes J, Schwab U, Lemke H and SteinH: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. IntJCancer31: 13-20, 1983.
3. Gerdes J, Lemke H, Baisch H, Wacker HH, SchwabU and SteinH: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. JImmunol133: 1710-1715, 1984.
4. Gerdes J, Li L, Schlueter C, etal: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. AmJPathol138: 867-873, 1991.
5. de Azambuja E, Cardoso F, de Castro G Jr, etal: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. BrJCancer96: 1504-1513, 2007.
6. Kontzoglou K, Palla V, KaraolanisG, etal: Correlation between Ki67 and breast cancer prognosis. Oncology84: 219-225, 2013.
7. Jones RL, Salter J, A'Hern R, etal: Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. BreastCancerResTreat119: 315-323, 2010.
8. Ellis MJ, CoopA, SinghB, etal: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. CancerRes63: 6523-6531, 2003.
9. Dowsett M, Smith IE, Ebbs SR, etal; IMPACT Trialists: Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. ClinCancerRes11: 951s-958s, 2005.
10. Dowsett M, Nielsen TO, A'Hern R, etal; International Ki-67 in Breast Cancer Working Group: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. JNatlCancerInst103: 1656-1664, 2011.
11. Cheang MC, Chia SK, Voduc D, etal: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNatlCancerInst101: 736-750, 2009.
12. Goldhirsch A, Wood WC, Coates AS, GelberRD, ThürlimannB and SennHJ; Panel Members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. AnnOncol22: 1736-1747, 2011.
13. Haroon S, Hashmi AA, KhurshidA, etal: Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. AsianPacJCancerPrev14: 4353-4358, 2013.
14. Pinder SE, Wencyk P, SibberingDM, etal: Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. BrJCancer71: 146-149, 1995.
15. Midulla C, De Iorio P, Nagar C, etal: Immunohistochemical expression of p53, nm23-HI, Ki67 and DNA ploidy: correlation with lymph node status and other clinical pathologic parameters in breast cancer. Anticancer Res 19: 4033-4037, 1999.
16. No authors listed: The World Health Organization. Histological typing of breast tumors. Neoplasma30: 113-123, 1983.
17. Robbins P, Pinder S, de Klerk N, etal: Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol26: 873-879, 1995.
18. Edge SB, Byrd DR, Compton CC, et al (eds.): AJCC Cancer Staging Manual. 7th edition. Springer, New York, NY, USA, 2009.
19. Hammond ME, Hayes DF, Dowsett M, etal: American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. JClinOncol28: 2784-2795, 2010.
20. Wolff AC, Hammond ME, HicksDG, etal; American Society of Clinical Oncology; College of American Pathologists: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practise guideline update. JClinOncol31: 3997-4013, 2013.
21. Fasching PA, Heusinger K, HaeberleL, etal: Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMCCancer11: 486, 2011.
22. Heusinger K, Jud SM, Haeberle L, etal: Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. BreastCancerResTreat135: 885-892, 2012.
23. Ferguson NL, Bell J, Heidel R, etal: Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. BreastJ19: 22-30, 2013.
24. Reyal F, Hajage D, Savignoni A, etal: Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoSOne8: e55901, 2013.
25. Yerushalmi R, Woods R, Ravdin PM, HayesMM and GelmonKA: Ki67 in breast cancer: prognostic and predictive potential. LancetOncol11: 174-183, 2010.
26. Kontzoglou K, Palla V, Karaolanis G, etal: Correlation between Ki67 and breast cancer prognosis. Oncology84: 219-225, 2013.
27. Mitrović O, Čokić V, Đikić D, etal: Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and apoptotic indexes with HER-2 gene amplification and TOP2A gene amplification and deletion in four molecular subtypes of breast cancer. TargetOncol9: 367-379, 2014.